REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Anti-Aging Skin Stack

Anti-Aging & Longevityintermediate

83

synergy

83
Share
Peptides

3

Avg Daily mcg

5,800

Level

intermediate

Added

May 17, 2026

Overview

The Anti-Aging Skin Stack combines the three most evidence-backed peptides for skin aging and longevity into a comprehensive protocol that targets collagen synthesis, cellular aging, and GH-driven tissue regeneration simultaneously. GHK-Cu (glycyl-L-histidyl-L-lysine copper) is the anchor of this stack. As a copper-binding tripeptide that naturally declines with age (from ~200ng/mL at age 20 to ~80ng/mL at 60), GHK-Cu activates over 4,000 human genes — more than any other known compound. For skin, it promotes collagen and elastin synthesis, activates fibroblasts, reduces inflammation, and protects against UV damage. Both topical and injectable forms have peer-reviewed human data supporting skin quality improvements. Epithalon works at the cellular aging level. By activating telomerase and regulating the pineal gland''s circadian signaling, it slows two fundamental mechanisms of skin aging: telomere shortening (which drives cellular senescence) and circadian rhythm disruption (which impairs the nighttime skin repair cycle). Epithalon is used in 10-day courses rather than continuously. CJC-1295 provides the GH axis component. GH decline is one of the primary drivers of skin thinning, reduced collagen density, and decreased healing capacity with age. By amplifying nocturnal GH pulses, CJC-1295 increases IGF-1-driven collagen production throughout the body, including skin. The combination of GHK-Cu (direct collagen synthesis) and CJC-1295 (hormonal collagen support) creates a more sustained and comprehensive collagen protection effect.

Dosing Protocol

GHK-Cu

Every day· subcutaneous or topical

Read more about GHK-Cu →

500 mcg

per dose

Epithalon

daily (10-day course)· subcutaneous

Read more about Epithalon →

5,000 mcg

per dose

CJC-1295

daily (before bed)· subcutaneous

Read more about CJC-1295 →

300 mcg

per dose

Goals & Evidence

Skin anti-agingCollagen productionReduced wrinklesSkin elasticityCellular longevity
Evidence tier:Human Data

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.